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Abstract 
Background: Axillary lymph node dissection (ALND) is an integral part of breast cancer treatment. It is required in about 40–50% of 
patients. The placement of a drain in the axilla after an operation is current surgical practice. Short surgical stay programmes increase 
operating efficiency and reduce medical care costs, without compromising quality of care. LigaSure
TM is a new haemostatic device that 
uses bipolar energy to seal vessels. The aim of this study is to determine whether axillary dissection with LigaSure
TM reduces the time of 
wound drainage, the duration of surgical intervention and the volume of drainage after treatment. 
Patients and methods: This study is a prospective randomized controlled trial. A total of 100 women with breast cancer who needed 
axillary dissection were randomized into the LigaSure
TM or conventional axillary dissection group. Levels I to III lymph node dissection 
was performed. A closed suction drain was always placed in the axilla and removed after 6–8 days or when fluid amount was <60 cc in 
the previous 24 hours. 
Results: There were no significant differences between the two groups when considering the duration of surgical procedure: average 
duration was 70.7 ± 24.66 minutes for LigaSure
TM patients, while in the conventional dissection group the mean was 70.6 ± 22.47 
minutes (p=0.98). Total amount of drained fluid was 624.49 cc in the LigaSure
TM axillary dissection group and 792.96 in the conventional 
ALND group; this difference did not achieve statistical significance (p=0.09); the duration of draining was also similar, with no statistical 
difference (p=0.15). 
Conclusions: The present study did not show clear advantages in LigaSure
TM use for ALND, although it represents a good haemostatic 
device, especially in abdominal surgery. 
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Introduction 
Axillary lymph node dissection (ALND) is an integral part of 
breast cancer therapy. It is required for patients with clinically 
positive lymph nodes and for those with clinically negative 
lymph nodes but with positive sentinel nodes. ALND is 
necessary in 40–50% of patients with breast cancer. Post-
operative complications include accumulation of 
serosanguinous fluid producing a seroma with a reported 
incidence of 5–80%[1–4]. The incidence of seroma has been 
shown to correlate with breast size, hypertension [5], presence 
of malignant nodes in the axilla, number of malignant nodes, 
previous surgical biopsy and use of heparin [6]. 
The origin of seroma is multi-factorial: it includes lymphorrhea 
from severed lymphatic vessels, local inflammation, surgically 
created dead space and use of electrocautery [7–9]. Currently 
accepted surgical practice for the prevention of seromas 
consists of insertion of a drain during the operation. A drain 
requires careful management and is usually removed when fluid 
output is reduced to approximately 40 cc per day, usually from 
seven to 14 days after the operation. A technique that would 
allow earlier drain removal or eliminate drains altogether might 
decrease morbidity and costs and enhance the patient's 
rehabilitation and satisfaction. 
LigaSure
TM (Valleylab, Boulder, CO, USA) is a device of bipolar 
haemostasis with automatic ‘switch-off’ when impedance 
reaches a critical level. LigaSure
TM seals blood vessels using a 
precise amount of energy and pressure that permanently 
changes the collagen and elastin pattern within the vessel wall. 
It ensures complete coagulation with minimal thermal spread 
and limited tissue charring [10,11]. The aim of this study was to 
determine whether axillary dissection with LigaSure
TM reduces 
the duration and amount of fluid drainage. 
 
Methodology 
This prospective randomized controlled trial was conducted at 
the Breast Unit of La Maddalena Cancer Centre in Palermo 
between January 2005 and December 2006. A total of 100 
women with breast cancer who required axillary dissection were 
recruited for the trial. Patients were randomized to the 
LigaSure
TM or conventional axillary dissection group at the time 
of surgery by closed envelope allocation; no stratification was 
used. 
All axillary dissections were done through an incision that 
followed a natural skin crease in the axilla. All branches of the 
axillary vein were divided and ligated at the level of the 
thoracoacromial vessels. The long thoracic and the 
thoracodorsal neurovascular bundles were preserved at all 
times. Level I to III lymph node dissection was performed 
routinely. A closed suction drain was placed in the axillary fossa 
in all cases. In the LigaSure
TM group both fat dissection and 
vessel sealing were performed using the medium-sized forceps. 
The drain was removed post-operatively from the 6–8th day or 
when the total drainage was <60 cc during the previous 24 
hours. Informed consent was obtained pre-operatively in 
accordance with the ethical standards of the Helsinki 
Declaration of 1975. All patients gave their consent after 
understanding the aim of the study, the different kinds of 
surgical procedures and the post-operative morbidity. 
The primary end point was whether the use of LigaSure
TM 
reduced the time needed for wound drainage compared to the 
control group, and the duration of surgical intervention. The 
secondary end point was whether LigaSure
TM reduced the 
volume of drainage after treatment. Safety was determined by 
comparing the incidence of adverse events. The person 
recording the volume of fluid collected from drains, whether a 
nurse, patient, family member or a member of the research 
staff, was blind to treatment assignment. 
Results are expressed as mean ± standard deviation or number 
(%). Group differences for continuous variables were assessed 
by Fisher's exact test. Group differences for other categorical 
variables were assessed by the chi-square test. Statistical 
significance was determined by using the alpha level of 0.05 
and the two-sided t test. 
 
Results 
One hundred patients were enrolled in the study and all were 
available for evaluation of the predefined end points and safety 
assessments. Patients' characteristics are listed in Table 1 . 
There were no significant differences in T and N stage between 
the two groups: the p values were 0.36 and 0.13, respectively. 
The distribution of performed surgical procedures was similar in 
LigaSure
TM and control patients: quadrantectomy with ALND 
dissection was 32 (64%) versus 22 (44%); modified radical 
mastectomy was 18 (36%) versus 28 (56%) with p=0.44. 
 2  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2007, 1:61 
 
 
Table 1: Characteristics of patients randomized to the LigaSure
TM group or conventional axillary dissection group 
Concomitant diseases (hypertension, diabetes mellitus and 
obesity) and a previous protocol of anti-blastic therapy were 
also considered and the results showed no significant 
differences between the two groups. 
To examine the hypothesis that the number of lymph nodes 
removed could influence the amount of lymphorrhea, the 
average of total nodes removed from each group was recorded 
and it was found that in the LigaSure
TM group the mean was 
higher than in the control group, 17.98 ± 5.52 versus 15.34 ± 
5.84 (p=0.02). No significance is reported for number of 
neoplastic nodes: p=0.38. The results of the trial are shown in 
Table 2. 
We did not find any statistically significant differences between 
the two groups when we considered the duration of the surgical 
procedure: average duration was 70.7 ± 24.66 minutes for 
LigaSure
TM patients, while in the conventional dissection group, 
the mean was 70.6 ± 22.47 minutes (p=0.98). Total amount of 
drained fluid was 624.49 cc in the LigaSure
TM axillary dissection 
group and 792.96 cc in the conventional axillary dissection 
group; this difference did not reach statistical significance 
(p=0.09); the duration of drain was also similar with no statistical 
difference (p=0.15). 
Seroma occurred in 22 patients operated with LigaSure
TM 
versus nine patients in which a traditional axillary dissection was 
performed. The p value recorded for this parameter was 
statistically significant (0.005). But when the average of fluid 
drained by punctures of the axillary region and the number of 
aspirations were considered, there was no significant difference. 
A low rate of surgical complications in both groups was 
recorded: only one patient had a wound dehiscence when 
LigaSure
TM was employed, while four dehiscences and one 
wound haemorrhage that required another operation were 
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Table 2: Clinical results of patients who underwent LigaSure
TM or conventional axillary dissection 
observed in the control group. Neither dehiscence nor post-
operative haemorrhage was statistically significant (p=0.17 and 
0.32, respectively). 
 
Discussion 
To date, breast cancer treatment can be performed in a day-
surgery regimen. Short surgical stay programmes increase 
operating efficiency and reduce medical care costs, without 
compromising quality of care [12,13]. Twenty-four-hour surgery 
stays can reduce average hospital costs by 36% [14]. In any 
case, there is the disadvantage that in patients who need 
axillary node dissection, it is necessary to place a suction drain 
to try to prevent seroma formation. 
The rich lymphatic drainage of the breast establishes the 
tendency for seroma formation within any closed space that 
results from breast surgery. The closed spaces of 
quadrantectomy cavities and axillary wounds can harbour 
seroma. Seroma formation under the skin flaps of axillary 
wounds impairs the healing process; the skin flaps tend to heal 
and adhere after 1–3 weeks, as evidenced by diminished drain 
output [7,15]. 
It is common practice to remove the drain when fluid output is 
reduced to approximately 40 cc per day, usually from seven to 
14 days after the operation. 
Seroma collections developing after drain discharge can be 
simply managed by percutaneous aspiration. It is usually well 
tolerated by patients and can be repeated as frequently as 
necessary to ensure that the skin flaps are densely adherent to 
the chest wall. Seroma aspiration is necessary in 10–80% of 
patients who underwent ALND, according to several series [15]. 
Some authors have compared drainage and no drainage in 
patients undergoing ALND; closed suction drainage appeared 
advantageous in decreasing the incidence and degree of 
seroma [16,17]. Talbot and Magarey considered 90 consecutive 
patients who had breast cancer undergoing ALND to (1) 
conventional prolonged closed-suction drainage, (2) two-day 
short-term drainage and (3) no drainage. In the first group, the 
drains were removed after a median of nearly ten days, with 
73% of cases requiring subsequent seroma aspiration. As 
expected, the short-term and no-drain groups required more 
frequent seroma aspirations (86% and 97%, respectively) [18]. 
It is obvious that home management of drains by patients, 
especially aged people, can be difficult; therefore, a technique 
that would allow earlier drain removal or eliminate drains 
altogether might decrease morbidity and costs and enhance the 
patient's rehabilitation and satisfaction. Another important 
aspect of early discharge is psychological acceptance. At the 
present time, some trials show that early discharge with drain is 
well accepted by the patients and does not increase the rate of 
psychological problems [12,19,20]. 
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Many measures have been attempted to avoid post-operative 
fluid effusion. Obliteration of dead space by chemical means 
has been attempted by many authors, with no clear benefit, 
sometimes followed by adverse effects. For example, 
sclerotherapy using tetracycline has led to severe pain on 
introduction of the drug, without any demonstrable long-term 
benefit [21,22]. Bovine thrombin has also proved unsuccessful 
in this regard. The employment of fibrin glue was encouraged 
after studies on animals [23,24], especially rats that underwent 
mastectomy, but in human studies no significant advantage was 
seen [25–27]. In a recent work, Johnson and Coll showed a 
lower rate of seroma formation using fibrin glue alone (36.8%) 
versus conventional drain placement (45%), but this difference 
was not significant. Moreover, aspirate volumes were 
significantly higher in the fibrin glue group (439 versus 121 ml; 
p=0.0015). These authors conclude that the higher cost 
involved, cumbersome technique and higher aspirate volumes 
tend to indicate that there is no advantage in using fibrin glue 
[28]. 
Pressure dressings have been attempted to reduce fluid 
effusion in the axilla after the operation. However, to immobilize 
the shoulder with a sling or to wrap a loose fitting bandage 
around the upper arm has shown no significant advantage in 
terms of seroma formation [3,29]. Moreover this approach 
carries the risk of possible long-term range of motion limitations 
and may even increase the risk of lymphedema. The Memorial 
Sloan Kettering Cancer Centre conducted a clinical trial that 
randomly assigned 135 patients undergoing ALND to receive a 
compression dressing for four days or standard wound 
coverage (all of them had conventional drainage as well). The 
study found no benefit from compression dressings. Both arms 
had similar total drainage volumes and drainage catheter 
duration; the compression arm furthermore had increased need 
for aspiration (mean number of punctures 2.9 in the 
compression, versus 1.8 in the standard dressing arm; p<0.1) 
[30]. 
Only one study has demonstrated the effectiveness of 
octreotide administration in the post-operative period after 
ALND, on amount and duration of lymphorrhea, but more 
randomized trials are needed to confirm the real advantage of 
its use [31]. In any case, octreotide administration did not 
influence the hospital stay, or the duration of drain. 
Some authors tested the effectiveness of different surgical 
cutting devices, such as Ultracision. A pilot study was set up to 
determine if it could reduce complications of seroma formation.
There was a little difference between the two groups in terms of 
hospital stay, volume or duration of post-operative drainage or 
subsequent aspiration of seroma [32]. 
In order to find a way to reduce complications after axillary 
dissection, we decided to employ LigaSure
TM. This system 
offers an excellent method for achieving bloodless dissection of 
vascular tissues. The combination of localized coagulation with 
minimal collateral thermal spread makes it an ideal device for 
surgical procedures. Technically, it is simple, easy to learn and 
quick to apply [10,11]. 
Our study was based on the hypothesis that accurate blood and 
lymphatic vessel sealing was related to minor fluid effusion in 
the post-operative period. Since LigaSure
TM seals vascular and 
lymphatic structures determining permanent changes in 
collagen and elastin patterns within the wall, we thought that 
this new haemostatic device could improve post-operative 
outcomes after ALND in terms of complications. 
A retrospective study concerning 187 patients who underwent 
ALND employing surgical clips or LigaSure
TM followed by 
drainage is reported in the literature. This study concluded that 
the duration of drainage was significantly shorter with 
LigaSure
TM but its benefits in term of fluid loss remains to be 
shown. Furthermore, its employment did not reduce the cost of 
hospitalization [33]. 
Also, our prospective study failed its aim: we did not find any 
clear advantage from its use in axillary node dissection. None of 
the considered parameters showed any significance in terms of 
p value. On the contrary, a larger number of seroma formations, 
after drain removal, were observed in the LigaSure
TM group 
than in the control group (22 versus 9; p<0.005). Moreover, the 
use of LigaSure
TM is more expensive than the traditional 
procedure: it requires an initial purchase of a generator at a cost 
of 21,000 euros and adds an additional cost to the operation 
(about 223 euros per disposable diathermy forceps). Hence, 
although it represents a good haemostatic device in abdominal 
surgery, where it decreases the duration of the operation, we 
think that its employment is not cost-effective in breast cancer 
treatment. 
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